Integra LifeSciences (NASDAQ:IART) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Integra LifeSciences (NASDAQ:IART) issued its quarterly earnings results on Monday. The life sciences company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.02, Briefing.com reports. Integra LifeSciences had a positive return on equity of 12.25% and a negative net margin of 0.42%. The firm had revenue of $380.80 million during the quarter, compared to the consensus estimate of $375.81 million. During the same period last year, the company earned $0.76 earnings per share. The company’s revenue for the quarter was down .4% on a year-over-year basis.

Integra LifeSciences Stock Down 1.9 %

Shares of NASDAQ:IART traded down $0.50 during mid-day trading on Thursday, hitting $26.20. 87,751 shares of the company traded hands, compared to its average volume of 1,100,250. The firm has a market cap of $2.03 billion, a P/E ratio of -289.67, a PEG ratio of 0.82 and a beta of 1.08. The company has a debt-to-equity ratio of 1.17, a quick ratio of 2.10 and a current ratio of 3.39. Integra LifeSciences has a 52-week low of $16.81 and a 52-week high of $45.42. The firm’s 50 day simple moving average is $18.90 and its 200 day simple moving average is $24.40.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on IART. Citigroup increased their price target on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a report on Tuesday. Bank of America cut their price objective on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research report on Monday, October 7th. Morgan Stanley increased their price objective on Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a research report on Monday, July 15th. BTIG Research upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Finally, JMP Securities dropped their price target on Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a research report on Tuesday, July 30th. Three analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $27.25.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.